Table 2 RS-1 and SCR7 effect on sgRNA +15 with a (100-30) ssODN.

From: Efficient correction of a deleterious point mutation in primary horse fibroblasts with CRISPR-Cas9

Treatment

n Sequenced

% INDELS

% HR

No Compound

33

81.8

0.0

15 µM RS-1

36

86.1

0.0

80 µM SCR7

43

79.1

0.0

Combined

43

81.0

0.0

  1. Comparisons of the RAD-51 stimulatory compound RS-1 and the DNA-Ligase IV inhibitory compound SCR7 or their combination when using sgRNA+15 a ssODN. The percent of INDELS was calculated as the number of sequenced colonies that showed insertions or deletions in the chromatograph analysis divided by the total number of sequenced colonies. No HR positive colonies were obtained. No differences were observed between treatment groups using a chi-square test (P < 0.05).
Back to article page